Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With DLBCL

Summary

The study will measure the safety, tolerability, and efficacy with acalabrutinib in combination with rituximab in treatment-naïve elderly and/or frail patients with diffuse large B-cell lymphoma (DLBCL), who are otherwise unsuitable for standard front line chemoimmunotherapy treatments.

Timeline

Start

2024-07-16

Primary completion

2029-04-22

Completion

2029-04-22

Drugs

Indications